TipRanks
AstraZeneca PLC (DE:ZEG)
FRANKFURT:ZEG
Germany Market
ZEG
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (ZEG) Stock Forecast & Price Target

16 Followers
See the Price Targets and Ratings of:

ZEG Analyst Ratings

Strong Buy
16Ratings
Strong Buy
14 Buy
2 Hold
0 Sell
Based on 16 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZEG Stock 12 Month Forecast

Average Price Target

€186.51
▲(29.79% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is €186.51 with a high forecast of €233.92 and a low forecast of €138.23. The average price target represents a 29.79% change from the last price of €143.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"137":"€137","234":"€234","161.25":"€161.3","185.5":"€185.5","209.75":"€209.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":233.923734,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€233.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":186.5055417342857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€186.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":138.227661,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€138.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[137,161.25,185.5,209.75,234],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141,148.14797953846153,155.29595907692308,162.4439386153846,169.59191815384617,176.7398976923077,183.88787723076922,191.03585676923075,198.1838363076923,205.33181584615386,212.4797953846154,219.6277749230769,226.77575446153844,{"y":233.923734,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141,144.50042628725274,148.0008525745055,151.50127886175824,155.001705149011,158.50213143626374,162.00255772351647,165.50298401076924,169.00341029802198,172.5038365852747,176.00426287252748,179.5046891597802,183.00511544703298,{"y":186.5055417342857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,141,140.78674315384615,140.57348630769232,140.36022946153847,140.1469726153846,139.9337157692308,139.72045892307693,139.50720207692308,139.29394523076922,139.0806883846154,138.86743153846155,138.6541746923077,138.44091784615387,{"y":138.227661,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":140.754,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.574,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.864,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":155.208,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.24,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.359,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.836,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157.849,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.475,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.95,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 72,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€233.92Average Price Target€186.51Lowest Price Target€138.23
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:ZEG
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
10/12/26
Bernstein Analyst forecast on DE:ZEG
Justin Smith
Bernstein
Bernstein
€238.65→€233.92
Buy
62.79%
Upside
Reiterated
10/07/26
Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)
Berenberg Bank Analyst forecast on DE:ZEG
Luisa Hector
Berenberg Bank
Berenberg Bank
€177.21
Buy
23.32%
Upside
Reiterated
10/07/26
AstraZeneca (AZN) Receives a Buy from Berenberg Bank
Jefferies Analyst forecast on DE:ZEG
Michael Leuchten
Jefferies
Jefferies
€206.75
Buy
43.88%
Upside
Reiterated
10/07/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on DE:ZEG
James Gordon CFA
Barclays
Barclays
€189.03
Buy
31.54%
Upside
Reiterated
10/05/26
Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on DE:ZEG
Sachin Jain
Bank of America Securities
Bank of America Securities
€194.94
Buy
35.66%
Upside
Reiterated
10/05/26
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
RBC Capital Analyst forecast on DE:ZEG
Trung Huynh
RBC Capital
RBC Capital
€171.31
Buy
19.21%
Upside
Reiterated
09/29/26
RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)
Deutsche Bank Analyst forecast on DE:ZEG
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
€138.23
Hold
-3.81%
Downside
Reiterated
09/29/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
J.P. Morgan Analyst forecast on DE:ZEG
Richard Vosser
J.P. Morgan
J.P. Morgan
€189.03
Buy
31.54%
Upside
Reiterated
09/29/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on DE:ZEG
Rajan Sharma
Goldman Sachs
Goldman Sachs
€195.24
Buy
35.87%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
UBS Analyst forecast on DE:ZEG
Colin White
UBS
UBS
€179.58
Buy
24.97%
Upside
Reiterated
09/16/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
HSBC Analyst forecast on DE:ZEG
Rajesh Kumar
HSBC
HSBC
€162.45→€164.46
Hold
14.44%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on DE:ZEG
Steve Scala
TD Cowen
TD Cowen
€214.04
Buy
48.95%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on DE:ZEG
Unknown Analyst
CICC
Not Ranked
CICC
€176.58
Buy
22.88%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
DZ BANK AG Analyst forecast on DE:ZEG
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:ZEG
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
10/12/26
Bernstein Analyst forecast on DE:ZEG
Justin Smith
Bernstein
Bernstein
€238.65→€233.92
Buy
62.79%
Upside
Reiterated
10/07/26
Bernstein Sticks to Its Buy Rating for AstraZeneca (AZN)
Berenberg Bank Analyst forecast on DE:ZEG
Luisa Hector
Berenberg Bank
Berenberg Bank
€177.21
Buy
23.32%
Upside
Reiterated
10/07/26
AstraZeneca (AZN) Receives a Buy from Berenberg Bank
Jefferies Analyst forecast on DE:ZEG
Michael Leuchten
Jefferies
Jefferies
€206.75
Buy
43.88%
Upside
Reiterated
10/07/26
Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on DE:ZEG
James Gordon CFA
Barclays
Barclays
€189.03
Buy
31.54%
Upside
Reiterated
10/05/26
Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)
Bank of America Securities Analyst forecast on DE:ZEG
Sachin Jain
Bank of America Securities
Bank of America Securities
€194.94
Buy
35.66%
Upside
Reiterated
10/05/26
AstraZeneca: Strong Pipeline and Growth Outlook Support Buy Rating and Unchanged 16,500 GBp Price Target
RBC Capital Analyst forecast on DE:ZEG
Trung Huynh
RBC Capital
RBC Capital
€171.31
Buy
19.21%
Upside
Reiterated
09/29/26
RBC Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)
Deutsche Bank Analyst forecast on DE:ZEG
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
€138.23
Hold
-3.81%
Downside
Reiterated
09/29/26
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
J.P. Morgan Analyst forecast on DE:ZEG
Richard Vosser
J.P. Morgan
J.P. Morgan
€189.03
Buy
31.54%
Upside
Reiterated
09/29/26
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
Goldman Sachs Analyst forecast on DE:ZEG
Rajan Sharma
Goldman Sachs
Goldman Sachs
€195.24
Buy
35.87%
Upside
Reiterated
09/29/26
AstraZeneca Secures $2 Billion Summit Therapeutics Oncology Partnership, Bolstering GI Cancer Pipeline and Supporting Buy Rating on AZN
UBS Analyst forecast on DE:ZEG
Colin White
UBS
UBS
€179.58
Buy
24.97%
Upside
Reiterated
09/16/26
UBS Sticks to Their Buy Rating for AstraZeneca (AZN)
HSBC Analyst forecast on DE:ZEG
Rajesh Kumar
HSBC
HSBC
€162.45→€164.46
Hold
14.44%
Upside
Reiterated
09/10/26
AstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBCAstraZeneca price target raised to 13,920 GBp from 13,750 GBp at HSBC
TD Cowen Analyst forecast on DE:ZEG
Steve Scala
TD Cowen
TD Cowen
€214.04
Buy
48.95%
Upside
Reiterated
08/31/26
Steve Scala Reiterates Buy on AstraZeneca Citing Above-Peer EPS Growth Outlook and Selective Pipeline Upside
CICC Analyst forecast on DE:ZEG
Unknown Analyst
CICC
Not Ranked
CICC
€176.58
Buy
22.88%
Upside
Initiated
08/24/26
AstraZeneca initiated with an Outperform at CICCAstraZeneca initiated with an Outperform at CICC
DZ BANK AG Analyst forecast on DE:ZEG
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
07/28/26
DZ BANK AG Sticks to Their Buy Rating for AstraZeneca (AZN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
ASNDAscendis Pharma
QNCXQuince Therapeutics
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
Luisa HectorBerenberg Bank
Success Rate
31/53 ratings generated profit
58%
Average Return
+2.48%
Copying Luisa Hector's trades and holding each position for 3 Months would result in 58.49% of your transactions generating a profit, with an average return of +2.48% per trade.
1 Year
Luisa HectorBerenberg Bank
Success Rate
36/53 ratings generated profit
68%
Average Return
+10.18%
Copying Luisa Hector's trades and holding each position for 1 Year would result in 67.92% of your transactions generating a profit, with an average return of +10.18% per trade.
2 Years
Luisa HectorBerenberg Bank
Success Rate
41/53 ratings generated profit
77%
Average Return
+17.37%
Copying Luisa Hector's trades and holding each position for 2 Years would result in 77.36% of your transactions generating a profit, with an average return of +17.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZEG Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
1
4
6
7
Buy
43
56
60
66
42
Hold
1
1
1
4
3
Sell
8
10
10
8
5
Strong Sell
0
0
0
0
0
total
52
68
75
84
57
In the current month, ZEG has received 49 Buy Ratings, 3 Hold Ratings, and 5 Sell Ratings. ZEG average Analyst price target in the past 3 months is 186.51.
Each month's total comprises the sum of three months' worth of ratings.

ZEG Financial Forecast

ZEG Earnings Forecast

Next quarter’s earnings estimate for ZEG is €2.32 with a range of €2.21 to €2.43. The previous quarter’s EPS was €2.35. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZEG is €2.32 with a range of €2.21 to €2.43. The previous quarter’s EPS was €2.35. ZEG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Sales Forecast

Next quarter’s sales forecast for ZEG is €14.30B with a range of €14.07B to €14.55B. The previous quarter’s sales results were €13.54B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.
Next quarter’s sales forecast for ZEG is €14.30B with a range of €14.07B to €14.55B. The previous quarter’s sales results were €13.54B. ZEG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZEG has Performed in-line its overall industry.

ZEG Stock Forecast FAQ

What is DE:ZEG’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 186.51.
    What is DE:ZEG’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 29.79% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy, which is based on 14 buy ratings, 2 hold ratings and 0 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 186.51. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €233.92 ,and the lowest forecast is €138.23. The average share price target represents 29.79% Increase from the current price of €143.7.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of DE:ZEG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.